Oncology & Cancer

Five-year extended hormone therapy no better in breast cancer

(HealthDay)—Extending hormone therapy by five years does not provide benefit over a two-year extension among postmenopausal women with hormone receptor-positive breast cancer who had received five years of adjuvant endocrine ...

Oncology & Cancer

New health guidance on breast cancer

In their draft guidance, the National Institute for Health and Care Excellence (NICE) said that postmenopausal women with a family history of breast cancer should now be offered the drug anastrozole, and not tamoxifen, to ...

page 1 from 2